Aimei Health Technology (AFJK)
Blank-check acquisition vehicle searching for healthcare-related businesses.
Something off on this page? Send us feedback.
Seeks to merge with a small-cap biopharmaceutical, medical-technology, diagnostic, or related-service business, using capital held in trust and shareholder approval to execute a combination. It is a pre-combination SPAC with no operating products, customers, segments, or revenue.
Operates as a blank-check acquisition vehicle, with no products, customers, operating segments, or operating revenue before a business combination. Public proceeds are held in trust while management evaluates a target, submits a deal for shareholder approval, and allows public shareholders to redeem.
Focuses its search on small-cap biopharmaceutical, medical-technology, diagnostic, and related-service businesses across North America, Europe, and Asia-Pacific, though its charter does not restrict the search by sector or region. Competes for targets and financing with other blank-check companies, financial sponsors, and strategic acquirers.
The proposed United Hydrogen transaction was terminated after missing its outside date. Execution now depends on identifying and completing a new qualifying combination before the applicable charter deadline; a small, part-time management team and affiliated extension financing support the process.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.5K · Total debt $2.2M · Total assets $12.5M · Shareholders' equity $8.0M
- Revenue
- $0
- Operating income
- −$192.3K
- Net income
- −$83.1K
No dividends on record.
| Institutions8 holders · as of Mar 31, 2026 | 30.78% | 974.7K shares | |
| Strategic holders1 holder · as of Feb 11, 2025 | 17.38% | 550.4K shares | |
| Otherremainder | 51.84% | 1.64M shares |
3.17M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
First Trust Capital Management L.P.Institution | 21.48% | 680,000 | 13Fas of Mar 31, 2026 |
Mizuho Securities USA LLCStrategic10 percent owner | 17.38% | 550,387 | Form 4filed Feb 11, 2025 ↗ |
Glazer Capital, LLCInstitution | 4.22% | 133,744 | 13Fas of Mar 31, 2026 |
Clear Street Group Inc.Institution | 2.63% | 83,337 | 13Fas of Mar 31, 2026 |
Karpus Management, Inc.Institution | 2.44% | 77,125 | 13Fas of Mar 31, 2026 |
| See all 19 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Blackstone
Scaled financial-sponsor rival with dedicated life-sciences capital.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aimei Health Technology | $12.50 | +2.04% | $38.7M | 179.0 | — | — | — |
| Blackstone | $137.41 | +0.42% | $165.28B | 30.4 | 21.3 | 10.3 | +2.4% |
| Median | 30.4 | 21.3 | 10.3 | +2.4% |